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ABSTRACT
Long-term administration of cyclosporine (CsA) has been
shown to cause hypercholesteremia, hypertriglyceridemia, and
elevations of plasma low-density and very low-density lipopro-
tein (LDL and VLDL) levels in humans. This study was under-
taken to explore the effects of CsA on expressions of the key
lipid regulatory enzymes and receptors. Thus, hepatic expres-
sions of cholesterol 7a-hydroxylase (the rate-limiting step in
cholesterol conversion to bile acids), LDL receptor, and high-
density lipoprotein (HDL) receptor proteins, as well as 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase ac-
tivity were determined in rats treated with CsA (18 mg/kg/day)
or placebo for 3 weeks. In addition, skeletal muscle and adi-
pose tissue expressions of lipoprotein lipase and VLDL recep-
tor were measured. Western blot analysis was used for all
protein measurements using appropriate antibodies against the
respective proteins. CsA-treated animals showed mild but sig-
nificant elevations of plasma cholesterol and triglyceride con-
centrations. This was associated with a marked down-regula-
tion of cholesterol 7a-hydroxylase in the liver and a severe
reduction of lipoprotein lipase abundance in skeletal muscle
and adipose tissue. However, hepatic LDL receptor and HDL
receptor expressions and HMG-CoA reductase activity were
not altered by CsA therapy. Likewise, skeletal muscle and
adipose tissue VLDL receptor protein expressions were unaf-
fected by CsA administration under the given condition. In
conclusion, CsA administration for 3 weeks resulted in a sig-
nificant reduction of hepatic cholesterol 7a-hydroxylase and
marked down-regulation of skeletal muscle and adipose tissue
lipoprotein lipase abundance in rats. The former abnormality
can contribute to hypercholesterolemia by limiting cholesterol
catabolism, whereas the latter may contribute to hypertriglyc-
eridemia and VLDL accumulation by limiting triglyceride-rich
lipoprotein clearance in CsA-treated animals.
Since its introduction and release as an anti-rejection
agent two decades ago, cyclosporine (CsA) has become the
cornerstone of immunosuppressive therapy in organ trans-
plant recipients. Administration of CsA is accompanied by a
variety of side effects, including hypertension, nephrotoxic-
ity, microvascular thrombosis, and hyperlipidemia.
Long-term administration of CsA has been reported to
raise plasma total cholesterol and triglyceride concentrations
and to increase plasma low-density lipoprotein (LDL) and
very low-density lipoprotein (VLDL) levels in humans (Raine
et al., 1988; Ballantyne et al., 1989; Drueke et al., 1991;
Schorn et al., 1991; Webb et al., 1992; Kuster et al., 1994;
Edwards et al., 1995; Verpooten et al., 1996). Moreover, CsA
administration enhances generation of oxygen-free radicals
leading to oxidation of lipoproteins and formation of
proatherogenic oxidized LDL (Lopez-Miranda et al., 1993;
Sutherland et al., 1995). It should be noted, however, that the
residual renal insufficiency and concomitant administration
of corticosteroids, diuretics, and beta blockers, which are
commonly used in transplant recipients, can independently
affect lipid metabolism. For instance, Arnadottir et al. (1991)
reported a significant elevation of serum cholesterol and
triglyceride concentrations in their transplant recipients
treated with CsA, compared with the non-CsA-treated group.
However, their CsA-treated group had a greater impairment
of renal function, received a higher corticosteroid dosage, and
were more frequently treated with diuretics and beta block-
ers. Moreover, multiple regression analysis failed to demon-
strate a clear association between CsA administration and
hyperlipidemia in the latter study (Arnadottir et al., 1991).
Thus, the presence of multiple confounding factors in the
clinical setting hinders the ability to draw definitive conclu-
sions as to the direct role of CsA in the pathogenesis of the
associated dyslipidemia.
Available data on the mechanisms of CsA-induced dyslip-
idemia are limited. We considered that a systematic study of
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the key lipid-regulatory factors might help to uncover the
molecular basis of CsA-induced hyperlipidemia. To this end,
we explored the effect of CsA therapy on hepatic 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase (the
rate-limiting enzyme in cholesterol synthesis), LDL, and
high-density lipoprotein (HDL) receptors (the critical factors
in metabolism of the cholesterol-rich LDL and HDL parti-
cles), and of cholesterol 7a-hydroxylase, (the rate-limiting
step in cholesterol catabolism to bile acids). In addition, we
determined the effects of CsA therapy on skeletal muscle and
adipose tissue abundance of lipoprotein lipase and the novel
VLDL receptor, which are the principal clearance pathways




Male Sprague-Dawley rats with an average body weight of 240 g
were randomized into CsA- and placebo-treated control groups (n 5
6 in each group). The animals were housed in a climate-controlled
light-regulated space with 12-h light (.500 lux) and dark (,5 lux)
cycles. They were fed regular rat chow and water ad libitum. Ani-
mals assigned to the CsA group were given a daily dose of CsA (18
mg/kg; Sigma Chemical Inc., St. Louis, MO) dissolved in olive oil by
gastric gavage. The control group received the vehicle (olive oil)
alone. Treatments were continued for 3 weeks. At the conclusion of
the study period, animals were placed in individual metabolic cages
for timed urine collections. Under general anesthesia (i.p. injection of
Nembutal, 50 mg/kg), liver, soleus muscle, and supratesticular fat
were harvested, and the animals were euthanized by exsanguina-
tion. The tissues were immediately frozen in liquid nitrogen and
stored at 270°C until processed. Serum total cholesterol and triglyc-
eride levels were measured using standard laboratory methods.
The CsA dosage used here was similar to that used in our earlier
studies of this model (Vaziri et al., 1998) and substantially lower
than the 25- to 60-mg/kg/day dosage used by other investigators in
the rat (Takenaka et al., 1992; Roullet et al., 1994; Oriji and Keiser,
1998). This was intended to minimize CsA-induced toxicity in the
study animals.
Western Blot Analyses
Western blot analysis was used to determine the abundance of the
following receptors and enzymes in the test tissues.
LDL Receptor Protein. Hepatic tissue LDL receptor abundance
was measured in plasma membrane preparation by Western blot
using mouse anti-LDL receptor antibody (Cortex Biochem Inc.,
Davis, CA) in a manner precisely the same as that described in our
earlier study (Vaziri and Liang, 1996b).
HDL Receptor Protein. Hepatic tissue HDL receptor abundance
was determined in the liver tissue protein preparation by Western
blot using a polyclonal HDL receptor antibody (Novus Biological Inc.,
Littleton, CO) as described in our earlier study (Liang and Vaziri,
1999).
VLDL Receptor Protein. Skeletal muscle and adipose tissue
VLDL receptor expressions were quantified by Western blot analysis
using a monoclonal antibody derived in our laboratory from the
IgG-GAG hybridoma cell line in a manner which was identical with
that described in our previous study (Vaziri and Liang, 1997).
Cholesterol 7a-Hydroxylase Protein. Cholesterol 7a-hydroxy-
lase protein mass was determined in hepatic tissue microsomal
preparation by Western blot using a rabbit anti-rat cholesterol 7a-
hydroxylase antibody (a generous gift from Professor John Y. L.
Chiang, Northwestern Ohio University) in a manner described in our
previous study (Liang et al., 1996).
Lipoprotein Lipase Protein. Lipoprotein lipase protein abun-
dance was determined in skeletal muscle and fat tissue preparations
by Western blot using a mouse anti-bovine lipoprotein lipase anti-
body (a gift from Professor John Brunzell, University of Washington)
as described in our earlier study (Vaziri et al., 1997).
HMG-CoA Reductase
HMG-CoA reductase enzymatic activity of the liver tissue was
determined using the procedures described in our earlier studies
(Vaziri and Liang, 1995).
Tissue-Free Cholesterol
Free cholesterol concentration in the liver tissue was determined
as described in our earlier studies (Vaziri and Liang, 1995).
Data Analysis
Student’s t test was used in statistical analysis of the data that are
presented as mean 6 S.E. P values less than .05 were considered
significant.
Results
The CsA-treated group exhibited a significant reduction in
hepatic cholesterol 7a-hydroxylase protein abundance com-
pared with that in the placebo-treated control rats (P , .002)
(Fig. 1). However, hepatic HMG-CoA reductase activity was
comparable in the two groups (4.0 6 0.1 versus 3.8 6 0.3
nmol/min/mg of protein in the CsA and control groups, re-
spectively, P 5 NS). No significant difference was found in
liver LDL receptor protein abundance between the two
groups (Fig. 2). Likewise, hepatic tissue HDL receptor pro-
tein mass was comparable in the two groups (Fig. 3). In
comparison with the control group, the CsA-treated rats
showed a marked down-regulation of lipoprotein lipase pro-
tein abundance in the adipose tissue (P , .001) (Fig. 4).
Similarly, lipoprotein lipase protein expression was signifi-
cantly reduced in the skeletal muscle of the CsA-treated rats
(P , .001) (Fig. 5). However, no significant difference was
observed in adipose tissue VLDL receptor protein expression
between the CsA- and placebo-treated rats (Fig. 6). Likewise,
CsA therapy did not significantly affect VLDL receptor pro-
tein expression in skeletal muscle (Fig. 7). Interestingly, free
Fig. 1. Representative Western blot and group data depicting hepatic
cholesterol 7a-hydroxylase (CH-7a-H) protein abundance in the CsA-
treated and control groups. n 5 6 in each group. *P , .002
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cholesterol concentration in the liver tissue was significantly
lower in the CsA-treated group compared with the control
group (3.7 6 0.3 versus 5.5 6 0.7 mg/g of wet tissue, P , .04).
No significant difference was found in creatinine clearance
between the CsA-treated rats (1.43 6 0.1 ml/min) and the
placebo-treated control animals (1.43 6 0.1 ml/min).
The CsA-treated group showed a mild but significant ele-
vation of serum total cholesterol concentration compared
with the control group (77.5 6 4.2 versus 61.9 6 1.7 mg/dl,
P , .01). Likewise, serum triglyceride level was higher in the
CsA-treated animals than the corresponding value found in
the control group (50.9 6 2.0 versus 42.5 6 2.6 mg/dl, P ,
.05).
Discussion
CsA-treated animals showed a significant reduction in he-
patic tissue abundance of cholesterol 7a-hydroxylase. This
enzyme is the rate-limiting step in cholesterol conversion to
bile acid, which is the principal pathway of cholesterol catab-
olism. Therefore, its down-regulation by CsA therapy can
potentially contribute to elevation of cholesterol level. In an
earlier study, Princen et al. (1991) demonstrated that CsA
blocks bile acid synthesis by cultured hepatocytes in vitro.
Down-regulation of hepatic cholesterol 7a-hydroxylase
shown in the CsA-treated animals here provides the molec-
ular basis of the in vitro studies by Princen et al. (1991).
Intracellular concentration of free cholesterol exerts a direct
regulatory role on hepatic cholesterol 7a-hydroxylase expres-
sion in the liver (Russell and Setchell, 1992). Down-regula-
tion of cholesterol 7a-hydroxylase found in our CsA-treated
animals may be due to depressed intracellular free choles-
terol concentration noted in these animals.
In contrast to cholesterol 7a-hydroxylase, hepatic HMG-
CoA reductase activity was not affected by CsA therapy in
the rats used in this study. Because HMG-CoA reductase is
the rate-limiting step in cholesterol synthesis, its normality
in the CsA-treated animals suggests that the associated rise
Fig. 2. Representative Western blot and group data depicting hepatic
LDL receptor (LDL-R) protein abundance in the CsA-treated and control
groups. n 5 6 in each group.
Fig. 3. Representative Western blot and group data depicting HDL re-
ceptor (HDL-R) protein abundance in the CsA-treated and control groups.
n 5 6 in each group.
Fig. 4. Representative Western blot and group data illustrating adipose
tissue lipoprotein lipase (LPL) protein abundance in the CsA-treated and
control groups. n 5 6 in each group. *P , .001
Fig. 5. Representative Western blot and group data illustrating skeletal
muscle lipoprotein lipase (LPL) protein abundance in the CsA-treated
and control groups. n 5 6 in each group. *P , .001
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in serum cholesterol is probably not due to enhanced hepatic
cholesterol synthesis.
Under normal conditions, as much as 80% of the circulat-
ing LDL particles are cleared by the liver primarily through
an LDL receptor-mediated process (Dietschy, 1995). Thus,
LDL receptor plays an important role in LDL metabolism.
Based on these observations, we considered that the reported
elevation of LDL cholesterol with CsA therapy could be due
to an acquired LDL receptor deficiency. However, the results
of this study revealed no discernible reduction in hepatic
LDL receptor protein abundance in the CsA-treated animals.
Thus, CsA administration at the given dosage for 3 weeks did
not alter hepatic LDL receptor protein mass in the rats. This
observation excluded a quantitative LDL receptor deficiency
in this model. It should be noted, however, that this study did
not examine the functional integrity of LDL receptor and its
binding affinity for LDL and, as such, cannot exclude possible
receptor dysfunction. LDL clearance by its receptor requires
LDL-LDL receptor binding. Thus, the rate of LDL clearance
by the liver is a function of LDL receptor abundance and the
binding affinity of LDL for its receptor. CsA therapy is asso-
ciated with increased generation of oxygen-free radicals lead-
ing to production of oxidized LDL (Apanay et al., 1994; Suth-
erland et al., 1995). Compared with the intact LDL, oxidized
LDL particles have a significantly lower binding affinity for
LDL receptor. It is, therefore, conceivable that the receptor-
mediated LDL uptake may be reduced despite normal LDL
receptor abundance in CsA-treated animals. Likewise, CsA
may directly bind to LDL particles and potentially alter their
composition and binding affinity. The available data do not
allow any conclusion with regards to the possible effects of
CsA on either LDL receptor or LDL structure or function.
Additional studies are needed to address these possibilities.
In contrast to this in vivo study demonstrating no significant
decrease in LDL receptor abundance, Rayyes et al. (1996)
have shown marked down-regulation of LDL receptor expres-
sion in CsA-treated HepG2 cells in vitro. The reason for the
difference between the latter in vitro study and this in vivo
study is not clear. It should be noted that intracellular free
cholesterol concentration exerts a negative feedback influ-
ence on hepatic LDL receptor expression (Cooper, 1989).
Despite the significant reduction in intracellular free choles-
terol concentration, hepatic LDL receptor failed to rise in the
CsA-treated group, thus reflecting a relative deficiency state.
Moreover, despite elevation of serum cholesterol concentra-
tion and normality of HMG-CoA reductase, cholesterol con-
centration in the hepatocyte was reduced. This phenomenon
points to a possible impairment of the receptor-mediated
cholesterol uptake by the liver.
HDL particles serve as carriers of cholesterol from periph-
eral tissues to the liver. The HDL-mediated reverse choles-
terol transport plays a major role in the cardiovascular pro-
tection against arteriosclerotic cardiovascular disease.
Cholesterol unloading in the liver by HDL particles depends
on the availability of the newly discovered hepatic HDL re-
ceptor (Acton et al., 1996). Cholesterol-rich HDL particles
transiently bind to HDL receptor, which facilitates transport
of cholesterol esters from HDL to hepatocytes. In addition,
HDL receptor facilitates the hydrolysis of HDL-borne triglyc-
erides by hepatic lipase and fatty acid uptake by hepatocytes.
Once lipid unloading has occurred, the lipid-depleted HDL
particle dissociates from the receptor to repeat the cycle
(Acton et al., 1996). We have recently demonstrated a
marked down-regulation of hepatic HDL receptor protein
expression in nephrotic syndrome (Liang and Vaziri, 1999).
By limiting the HDL-mediated reverse cholesterol transport,
HDL receptor deficiency can potentially contribute to arte-
riosclerotic vascular disease. Because chronic CsA adminis-
tration can result in vasculopathy, we wondered whether
CsA therapy affects HDL receptor abundance. The results of
this study showed no significant difference in hepatic HDL
receptor protein expression between the CsA- and vehicle-
treated control rats. This observation excluded a quantitative
HDL receptor deficiency in CsA-treated rats under the given
experimental conditions. However, the available data do not
allow any conclusion about the receptor function and the
receptor ligand interaction, which await future investiga-
tions.
Lipoprotein lipase is expressed in a variety of tissues, most
notably skeletal muscle, myocardium, and adipose tissue. In
the presence of its cofactor, apolipoprotein C-II, lipoprotein
Fig. 6. Representative Western blot and group data illustrating adipose
tissue VLDL receptor (VLDL-R) protein abundance in the CsA-treated
and control groups. n 5 6 in each group.
Fig. 7. Representative Western blot and group data illustrating skeletal
muscle VLDL receptor (VLDL-R) protein abundance in the CsA-treated
and control groups. n 5 6 in each group.
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lipase hydrolyzes triglycerides contained in the triglyceride-
rich lipoproteins, namely, VLDL and chylomicrons. This re-
sults in the release of free fatty acids that are taken up by
myocytes for energy production or by adipocytes for energy
storage. Moreover, lipolytic action of lipoprotein lipase trans-
forms VLDL to intermediate-density lipoprotein (IDL) and
chylomicron to chylomicron remnants that undergo further
transformation and eventual uptake through LDL receptor
or LDL receptor-related protein pathways. Inherited lipopro-
tein lipase deficiency is associated with hypertriglyceridemia
and impaired chylomicron and VLDL clearance, as well as
triglyceride enrichment of various lipoproteins. We have re-
cently shown marked down-regulation of lipoprotein lipase in
animals with chronic renal failure and nephrotic syndrome,
conditions that are associated with hypertriglyceridemia and
impaired triglyceride-rich lipoprotein clearance (Vaziri and
Liang, 1996a; Liang and Vaziri, 1997b). We, therefore, con-
sidered that hypertriglyceridemia and elevated VLDL con-
centration known to occur in CsA-treated patients (Raine et
al., 1988; Ballantyne et al., 1989; Drueke et al., 1991; Schorn
et al., 1991; Webb et al., 1992; Kuster et al., 1994; Edwards et
al., 1995; Verpooten et al., 1996; Verzola et al., 1999) may be,
in part, due to lipoprotein lipase deficiency. The results of
this study showed marked reductions of both skeletal muscle
and adipose tissue lipoprotein lipase abundance in CsA-
treated rats, thus supporting our original hypothesis. Be-
cause lipoprotein lipase is a major pathway for fatty acid
uptake by myocytes and adipocytes, its deficiency in CsA-
treated subjects impacts not only plasma lipoprotein metab-
olism but also energy production and storage capacity. As
noted earlier, chronic renal failure is associated with lipopro-
tein lipase deficiency (Liang and Vaziri 1997a; Vaziri et al.,
1997). However, the CsA-treated animals used here did not
have renal insufficiency as evidenced by normal creatinine
clearance values. Thus, the observed lipoprotein lipase defi-
ciency in our CsA-treated animals was not due to renal
failure.
Discovery of the VLDL receptor several years ago unrav-
eled a previously unknown pathway of VLDL clearance (Ta-
kahashi et al., 1992). The VLDL receptor belongs to the large
LDL receptor gene family with distinctly different ligand
specificity and tissue distribution compared with LDL recep-
tor. For instance, the VLDL receptor binds and internalizes
triglyceride-rich VLDL and IDL but not LDL particles. More-
over, it is primarily expressed in skeletal muscle, myocar-
dium, and adipose tissue (Takahashi et al., 1992; Jokinen et
al., 1994), whereas LDL receptor is expressed in the liver,
steroidogenic glands, and other tissues. We have recently
found marked down-regulation of VLDL receptor expression
in rats with chronic renal failure (Vaziri and Liang, 1997)
and nephrotic syndrome (Liang and Vaziri, 1997a), condi-
tions that are marked by hypertriglyceridemia and elevated
VLDL levels. Based on these considerations, we asked
whether or not the reported CsA-induced elevation of triglyc-
eride and VLDL levels is associated with VLDL receptor
deficiency. The study revealed no discernible difference in
VLDL receptor protein abundance in either the skeletal mus-
cle or adipose tissue between the CsA-treated and control
groups. Thus, CsA administration in rats under the given
conditions does not lead to quantitative modification of VLDL
receptor protein expression. It should be noted that lipopro-
tein lipase and apolipoprotein E have been shown to signifi-
cantly enhance VLDL receptor activity, whereas heparinase
has been shown to depress VLDL receptor activity (Taka-
hashi et al., 1995). Thus, lipoprotein lipase appears to en-
hance VLDL and IDL binding to the VLDL receptor by form-
ing a bridge between these apolipoprotein E-containing
lipoproteins and heparin sulfate proteoglycans and by pro-
teolytic modification of these particles (Takahashi et al.,
1995). In view of the regulatory action of lipoprotein lipase on
VLDL receptor activity, it is reasonable to assume that al-
though CsA does not change VLDL receptor abundance, it
can potentially depress its functional activity through induc-
tion of lipoprotein lipase deficiency.
In conclusion, administration of CsA to rats for 3 weeks
resulted in significant down-regulation of hepatic cholesterol
7a-hydroxylase, the rate-limiting step in cholesterol conver-
sion to bile acids. In addition, CsA therapy resulted in
marked down-regulation of skeletal muscle and adipose tis-
sue lipoprotein lipase expression. If true in humans, the
latter abnormality can potentially contribute to hypertriglyc-
eridemia and elevation of VLDL level, whereas the former
can contribute to hypercholesterolemia in CsA-treated pa-
tients.
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